8-K: BIOLASE Reports Modest Revenue Growth in 2023, Expects Acceleration in 2024

BIOLASE achieved a 1% revenue increase in 2023 despite industry challenges and anticipates stronger growth and positive adjusted EBITDA in 2024.

Summary

• BIOLASE reported a 1% increase in net revenue for 2023, reaching $49.2 million, compared to $48.5 million in 2022.
• U.S. laser revenue decreased by 10% to $18.4 million, while U.S. consumables and other revenue increased by 31%.
• International laser revenue grew by 6% to $11.7 million, but international consumables and other revenue decreased by 3%.
• The company's gross margin improved slightly to 34% from 33% in the previous year.
• Operating expenses decreased by 16% to $34.7 million, resulting in a 29% reduction in operating loss to $17.9 million.
• BIOLASE had $6.6 million in cash and cash equivalents as of December 31, 2023.
• Following a $7.0 million equity raise in February 2024, the company believes it has sufficient liquidity to execute its growth strategies.
• The net loss attributable to common stockholders for 2023 was $37.6 million, or $29.44 per share.
• Adjusted EBITDA for 2023 was a loss of $12.8 million, or $10.00 per share.
• BIOLASE expects first-quarter 2024 net revenue to exceed $10.0 million and full-year revenue to increase between 6% and 8%, reaching $52 million to $53 million.
• The company anticipates achieving positive adjusted EBITDA for the full year 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with modest revenue growth and a net loss, but also highlights positive trends in consumable sales, cost reductions, and a positive outlook for 2024. The company's ability to achieve positive adjusted EBITDA in 2024 will be a key factor in future performance.

Positives

• The company achieved modest revenue growth despite a challenging economic environment.
• Consumable sales saw significant growth, indicating increased utilization of their installed base.
• The Waterlase Trial Program is proving successful with a 45% sales conversion rate.
• Cost-saving measures through in-house manufacturing have been effective.
• Operating expenses have been reduced by 16%, improving profitability.
• The company expects to achieve positive adjusted EBITDA for the full year 2024.
• A recent equity raise of $7.0 million has improved the company's liquidity.

Negatives

• U.S. laser revenue decreased by 10% year-over-year.
• International consumable and other revenue decreased by 3% year-over-year.
• The company reported a net loss of $37.6 million for the year.
• Adjusted EBITDA was still a loss of $12.8 million for the year.

Risks

• The company faces challenges from a difficult spending environment and higher interest rates.
• There is uncertainty regarding customer acceptance of new product offerings and market changes.
• The company acknowledges the risk of adverse changes in general economic and market conditions.
• The company faces competitive pressures, including pricing pressures and new product introductions.
• The company has a history of losses and may not achieve profitability.
• The company's future performance is subject to the risks and uncertainties described in its SEC filings.

Future Outlook

BIOLASE expects continued revenue growth in 2024, with full-year revenue projected to increase between 6% and 8% and anticipates achieving positive adjusted EBITDA for the full year.

Management Comments

• John Beaver, President and Chief Executive Officer of BIOLASE, stated that initiatives enabled modest revenue growth in 2023 despite a challenging spending environment.
• Management believes that increased interest in their dental lasers will drive greater awareness and allow them to accelerate revenue growth in 2024.
• Management expects greater adoption of dental lasers, coupled with expanded gross margins and lower operating expenses, will allow them to meet revenue and profitability objectives for 2024.

Industry Context

The dental laser market is competitive, and BIOLASE is working to increase adoption of its products. The company's focus on recurring revenue through consumables and subscriptions aligns with industry trends towards more predictable revenue streams. The company is also working to improve its cost structure to improve profitability.

Comparison to Industry Standards

• While BIOLASE's overall revenue growth of 1% is modest, the 20% increase in consumable sales indicates strong customer engagement and recurring revenue potential, which is a key metric for medical device companies.
• Companies like Align Technology (ALGN) in the dental space have demonstrated the value of recurring revenue models, and BIOLASE's focus on this area is a positive sign.
• The reduction in operating expenses by 16% is a significant improvement, as many medical device companies struggle with high overhead costs. This is comparable to companies like Straumann (STMN) that have focused on operational efficiency.
• However, the 10% decrease in U.S. laser revenue is a concern, as the U.S. market is a key driver for many medical device companies. This contrasts with companies like Dentsply Sirona (XRAY) that have shown more consistent growth in their core markets.
• The company's goal to achieve positive adjusted EBITDA in 2024 is a critical step, as many smaller medical device companies struggle to reach profitability. This is a key difference compared to larger, more established players in the industry.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and future growth prospects.
• Employees will be affected by the company's operational changes and growth strategies.
• Customers will benefit from the company's innovative laser technology.
• Suppliers will be impacted by the company's manufacturing and supply chain decisions.
• Creditors will be impacted by the company's financial health and ability to repay debts.

Next Steps

• BIOLASE will host a conference call to discuss the results and answer questions.
• The company will focus on increasing adoption of its laser systems and consumables.
• BIOLASE will continue to improve its operations and cost structure.
• The company will work towards achieving positive adjusted EBITDA for the full year 2024.

Key Dates

Keywords

dental lasers, BIOLASE, revenue growth, consumables, adjusted EBITDA, medical devices, laser technology, financial results, operating expenses, profitability